Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation

Completed · Phase 2

Conditions studied: Leukemia, Lymphoma, Allogeneic Haematopoietic Stem Cell Transplantation, Acute Lymphoblastic Leukemia

In brief

The goal of this clinical research study is to test the safety of giving clofarabine in combination with busulfan, followed by an allogeneic (from a donor) stem cell transplant, in patients with advanced leukemia or lymphoma.

Key facts

Study ID

NCT00990249

Run by

M.D. Anderson Cancer Center

People needed

120

Starts

2009-10-01

Expected to finish

2016-05-01

Last updated by the study team

2018-08-07

Who can join

Age: any, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with biopsy-proven acute lymphoblastic leukemia, acute lymphoblastic lymphoma, or acute biphenotypic leukemia in remission or relapse.
• Adequate renal function, as defined by estimated serum creatinine clearance >60 ml/min.
• Bilirubin equal or less than 1.5 (unless Gilbert's Syndrome), serum glutamate pyruvate transaminase (SGPT) <3 X upper limit of normal and alkaline phosphatase <2 X upper limit of normal.
• Adequate pulmonary function with forced expiratory volume at one second (FEV1), forced vital capacity (FVC) and diffusion capacity of lung for carbon monoxide (DLCO) at least 45% of expected corrected for hemoglobin. Children unable to perform pulmonary functions must have an oxygen saturation greater than 92% at room air.
• Adequate cardiac function with left ventricular ejection fraction at least 45% on appropriate medical therapy. No uncontrolled arrhythmias or symptomatic cardiac disease.
• Zubrod performance status <2 or Lansky/Karnofsky PS equal or greater to 70%.
• Patients must have a related, genotypically HLA identical donor, or they must have a unrelated donor who is 8/8 HLA match by high resolution typing.
• Patient or patient's legal representative, parent(s) or guardian should provide written informed consent. Assent of a minor if participant's age is at least seven and less than eighteen years.
• Negative Beta Human Chorionic Gonadotropin (HCG) test in a woman with child bearing potential defined as not post-menopausal for 12 months and no previous surgical sterilization.

You may not qualify if…

• Patients with unresolved grade >2 non-hematologic toxicity from previous therapy. Patients with grade 2 toxicity will be eligible at the discretion of the PI.
• Patients with active central nervous system (CNS) disease.
• Evidence of acute or chronic active hepatitis or cirrhosis.
• Uncontrolled infection, including HIV, HTLV-1, hepatitis B or hepatitis C viremia.
• Patients greater than 65 years-old.
• Prior autologous or allogeneic hematopoietic stem cell transplant.

Where it is running

• University of Texas MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.